

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	HEALIUS LIMITED
<b>ABN</b>	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael Stanford
<b>Date of last notice</b>	4 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Mrs Sally Stanford
<b>Date of change</b>	21 November 2024
<b>No. of securities held prior to change</b>	32,468 Sally Stanford
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	40,000
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$1.33 per Ordinary Share

+ See chapter 19 for defined terms.

**Appendix 3Y  
Change of Director's Interest Notice**

---

<p><b>No. of securities held after change</b></p>	<p>1. Sally Stanford - 32,468 2. Michael Stanford – 40,000</p>
<p><b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>On-market trade</p>

**Part 2 – Change of director's interests in contracts** Not applicable

**Part 3 – +Closed period**

<p><b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b></p>	<p>N/A</p>
<p><b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b></p>	<p>N/A</p>
<p><b>If prior written clearance was provided, on what date was this provided?</b></p>	<p>N/A</p>

Authorised by the Company Secretary.

Mary Weaver  
Company Secretary  
Date: 25 November 2024

---

+ See chapter 19 for defined terms.